![[personal profile]](https://www.dreamwidth.org/img/silk/identity/user.png){kind=small}
Poking around a little, I found that (a) Evusheld is supposed to provide at least six months of protection, but (b) it may be less effective against omicron than against earlier variants, so (c) the FDA doubled the dosage last month, from 150 mg each of the two antibodies, to 300 mg each.
This is for pre-exposure prophylaxis, or PrEP, an acronym that some articles are assuming (correctly, in my case) that the reader knows.
The protection is at its strongest right now, and will diminish over time because the number of antibodies in the patient's system diminishes.
Putting this here largely for my own reference.
ETA 3/18: I found the AstraZeneca factsheet on Evusheld for medical providers, which includes the pharmacology: half-life is a mean 87.9 days (SD 13), which makes six months of protection seem plausible. (The person I talked to yesterday was guessing that the half-life would be about four weeks, based on the half-life of IgG treatments for hepatitis B.
[apparently it's "Evusheld," no i.}
This is for pre-exposure prophylaxis, or PrEP, an acronym that some articles are assuming (correctly, in my case) that the reader knows.
The protection is at its strongest right now, and will diminish over time because the number of antibodies in the patient's system diminishes.
Putting this here largely for my own reference.
ETA 3/18: I found the AstraZeneca factsheet on Evusheld for medical providers, which includes the pharmacology: half-life is a mean 87.9 days (SD 13), which makes six months of protection seem plausible. (The person I talked to yesterday was guessing that the half-life would be about four weeks, based on the half-life of IgG treatments for hepatitis B.
[apparently it's "Evusheld," no i.}
Tags: